Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients

Intramuscular (IM) and Intradermal (ID) vaccination against hepatitis B (HB) are efficient in hemodialysis patients. We retrospectively analysed the response of 32 patients during 48 consecutive months and compared the results of the two vaccination routes using the recombinant vaccine (Engerix, SKB). Thirteen patients were vaccinated with 5 meg ID every 2 weeks (total 8 doses), plus an IM dose on month (M) 12 (group A). Nineteen patients (group B) were vaccinated with 4 IM doses of 20 meg each, on months M0, 1, 2 and 12. HB antibodies were measured on M5, M11, M13, M24, M36 and M48. An additional 20 meg IM dose was given with titers below 10 mlU/ml. Seroconversion, seroprotection and antibody levels were equivalent in both groups up to M13; with the exception of seroconversion rates, a significantly different response was observed afterwards (A/B, in mlU/ml): M5: 399 +/- 107 vs 342 +/- 69, M13: 536 +/- 118 vs 673 +/- 61, M24. 278 +/- 94 vs 595 +/- 81, P=0.02, and M48. 68 +/- 29 vs 565 +/- 92, P=0.003. Early HB(s)AB levels did not correlate with those found four years later in both groups. An additional booster dose was given 8 times in 4 group A patients (1-3 doses/patient) and 3 times in 1 group B patient. Immune response to HB vaccine in hemodialysis patients is initially equivalent by both immunization routes. Late antibody titers were found significantly lower in ID immunization with more frequent booster doses needed.